The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Self-citationRichardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
Cited by
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 414
In vivo models of angiogenesis
Norrby, K. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00423.x · Cited by 286
Reddy, N., Hernandez‐Ilizaliturri, F. J., Deeb, G., Roth, M., Vaughn, M., Knight, J., Wallace, P., & Czuczman, M. S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06841.x · Cited by 260
Melchert, M., & List, A. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.022 · Cited by 246
Morschhauser, F., Fitoussi, O., Haioun, C., Thieblemont, C., Quach, H., Delarue, R., Glaisner, S., Gabarre, J., Bosly, A., Lister, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.029 · Cited by 131
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen, C. I., Bergsagel, P. L., Paul, H., Xu, W., Lau, A., Dave, N., Kukreti, V., Wei, E., Leung-Hagesteijn, C., Li, Z. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8133 · Cited by 115
Phase I study of oral lenalidomide in patients with refractory metastatic cancer
Dahut, W. L., Aragon‐Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., & Figg, W. D. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009335001 · Cited by 56
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
Choueiri, T. K., Dreicer, R., Rini, B. I., Elson, P., Garcia, J. A., Thakkar, S. G., Baz, R. C., Mekhail, T. M., Jinks, H. A., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22290 · Cited by 54
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Metadata
- Authors
- Dredge, K., Horsfall, R., Robinson, S. P., Zhang, L.-H., Lu, L., Tang, Y., Shirley, M. A., Muller, G., Schafer, P., Stirling, D., Dalgleish, A. G., & Bartlett, J. B.
- Venue
- Microvascular Research
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 69
- Issue
- 1-2
- Pages
- 56-63
- ISSN
- 0026-2862 (ISSN-L)
- OpenAlex
- W1964370179
- Cited by
- 268
- References
- 22
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.